176 related articles for article (PubMed ID: 31416839)
1. Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression.
Wettersten HI; Weis SM; Pathria P; Von Schalscha T; Minami T; Varner JA; Cheresh DA
Cancer Res; 2019 Oct; 79(19):5048-5059. PubMed ID: 31416839
[TBL] [Abstract][Full Text] [Related]
2. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
[TBL] [Abstract][Full Text] [Related]
3. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.
Mulgrew K; Kinneer K; Yao XT; Ward BK; Damschroder MM; Walsh B; Mao SY; Gao C; Kiener PA; Coats S; Kinch MS; Tice DA
Mol Cancer Ther; 2006 Dec; 5(12):3122-9. PubMed ID: 17172415
[TBL] [Abstract][Full Text] [Related]
4. CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy.
Cao A; Yi J; Tang X; Szeto CW; Wu R; Wan B; Fang X; Li S; Wang L; Wang L; Li J; Ye Q; Huang T; Hsu K; Kabbarah O; Zhou H
Cancer Res Commun; 2022 Nov; 2(11):1404-1417. PubMed ID: 36970051
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
6. Blockade of DC-SIGN
Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
[TBL] [Abstract][Full Text] [Related]
7. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
8. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
9. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
[TBL] [Abstract][Full Text] [Related]
10. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
Pander J; Heusinkveld M; van der Straaten T; Jordanova ES; Baak-Pablo R; Gelderblom H; Morreau H; van der Burg SH; Guchelaar HJ; van Hall T
Clin Cancer Res; 2011 Sep; 17(17):5668-73. PubMed ID: 21788356
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
Kurdi AT; Glavey SV; Bezman NA; Jhatakia A; Guerriero JL; Manier S; Moschetta M; Mishima Y; Roccaro A; Detappe A; Liu CJ; Sacco A; Huynh D; Tai YT; Robbins MD; Azzi J; Ghobrial IM
Mol Cancer Ther; 2018 Jul; 17(7):1454-1463. PubMed ID: 29654064
[TBL] [Abstract][Full Text] [Related]
12. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
13. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.
Zhang M; Wen B; Anton OM; Yao Z; Dubois S; Ju W; Sato N; DiLillo DJ; Bamford RN; Ravetch JV; Waldmann TA
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10915-E10924. PubMed ID: 30373815
[TBL] [Abstract][Full Text] [Related]
14. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
[TBL] [Abstract][Full Text] [Related]
16. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.
Eisinger S; Sarhan D; Boura VF; Ibarlucea-Benitez I; Tyystjärvi S; Oliynyk G; Arsenian-Henriksson M; Lane D; Wikström SL; Kiessling R; Virgilio T; Gonzalez SF; Kaczynska D; Kanatani S; Daskalaki E; Wheelock CE; Sedimbi S; Chambers BJ; Ravetch JV; Karlsson MCI
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32005-32016. PubMed ID: 33229588
[TBL] [Abstract][Full Text] [Related]
17. Macrophages are critical effectors of antibody therapies for cancer.
Weiskopf K; Weissman IL
MAbs; 2015; 7(2):303-10. PubMed ID: 25667985
[TBL] [Abstract][Full Text] [Related]
18. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
[TBL] [Abstract][Full Text] [Related]
19. Precise Delivery of Nanomedicines to M2 Macrophages by Combining "Eat Me/Don't Eat Me" Signals and Its Anticancer Application.
Tang Y; Tang Z; Li P; Tang K; Ma Z; Wang Y; Wang X; Li C
ACS Nano; 2021 Nov; 15(11):18100-18112. PubMed ID: 34751571
[TBL] [Abstract][Full Text] [Related]
20. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
Zhu Q; Wu X; Wu Y; Wang X
Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]